Considering the significant improvement of SDF-1 on the therapeutic effects of human ERCs, SDF-1-pretreated ERCs could also play a significant role in treating other diseases such as autoimmune hepatitis, acute pancreatitis, and acute myocardial infarction. The gene discussed is CXCL12; the disease is myocardial infarction.